Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Supportive care to ensure optimal quality of life is an essential component of cancer care and symptom control across the lifespan. Ongoing advances in cancer treatment, increasing toxicity from many novel treatment regimes, and variations in access to care and cancer outcomes across the globe and resource settings present significant challenges for supportive care delivery. To date, no overarching framework has been developed to guide supportive care development worldwide. As an initial step of the Multinational Association of Supportive Care in Cancer (MASCC) Supportive Care 2030 Movement, we developed a targeted, unifying set of ambition statements to envision the future of supportive cancer care.
Methods: From September 2022 until June 2023, we used a modified Delphi methodology to develop and attain consensus about ambition statements related to supportive cancer care. Leaders of MASCC Study Groups were invited to participate in an Expert Panel for the first two Delphi rounds (and a preliminary round to suggest potential ambition statements). Patient Advocates then examined and provided input regarding the ambition statements.
Findings: Twenty-seven Expert Panelists and 11 Patient Advocates participated. Consensus was attained on 13 ambition statements, with two sub-statements. The ambition statements addressed global standards for guideline development and implementation, coordinated and individualized care, dedicated supportive oncology services, self-management, needs for screening and actions, patient education, behavioral support, financial impact minimization, comprehensive survivorship care, and timely palliative care, reflecting collaboration, coordination and team-based approach across all levels.
Interpretation: This study is the first to develop shared ambitions for the future of supportive cancer care on a global level. These ambition statements can facilitate a coordinated, resource-stratified, and person-centered approach and inform research, education, clinical services, and policy efforts.
Funding: This project received funding support from Prof Raymond Chan's NHMRC Investigator Grant (APP1194051).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415959 | PMC |
| http://dx.doi.org/10.1016/j.eclinm.2024.102825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Where comfort and nutrition meet: A case series of children with severe neurologic impairment receiving home parenteral nutrition at the end of life.
Nutr Clin Pract
September 2025
Department of Pediatrics, Mayo Clinic, Rochester, Minnesota, USA.
Home parenteral nutrition (HPN) is a life-sustaining therapy traditionally used as a bridge to enteral autonomy or intestinal transplantation. Increasingly, it is used for intractable feeding intolerance (IFI), which can occur near the end of life (EOL) in children with severe neurological impairment (SNI). In these cases, HPN use differs from its historical role and requires tailored outpatient planning.
View Article and Find Full Text PDFEstimating Health State Utilities for IDH-Mutant Diffuse Glioma.
Pharmacoecon Open
September 2025
Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.
Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.
View Article and Find Full Text PDFProspective validation of the Nottingham Hip Fracture Score for predicting 1-year mortality in a Spanish cohort.
Br J Anaesth
September 2025
Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca i Innovació en Ciències de la Vida i la Salut a la Catalunya Central (IrisCC), Vic, Barcelona, Spain; Department of Internal Medicine, Hospital d'Olot i comarcal de la Garrotxa, Olot, Girona, Spain; Faculty of Medicine, Univer
Pharmacogenetics in oncology: Unveiling its potential in treatment personalization and beyond.
Bull Cancer
September 2025
Department of Pathology and Medical Biology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
The effectiveness and tolerability of medicines can vary considerably from person to person, even at the same dose. This variation is influenced by many factors, including constitutional genetic characteristics. In fact, some people have genetic variations that are common and neutral in the population, known as polymorphisms, which can affect drug metabolism or make them more susceptible to certain adverse effects.
View Article and Find Full Text PDFPalliative Care in Parkinson's Disease and other Movement Disorders. Recommendations and protocol of a multidisciplinary group of experts.
Neurologia (Engl Ed)
September 2025
Servicio de Neurología, CHUAC, Complejo Universitario de A Coruña, A Coruña, Spain.
Introduction: One of the current challenges in Parkinson's disease (PD) and other movement disorders (MD) is how and when to apply palliative care. Aware of the scarce training and implementation of this type of approach, we propose some consensual recommendations for palliative care (PC) in order to improve the quality of life of patients and their environment.
Material And Methods: After a first phase of needs analysis through a survey carried out on Spanish neurologists and a review of the literature, we describe recommendations for action structured in: palliative care models, selection of the target population, when, where and how to implement the PC.